Aprokam 50 mg inj. opl. (pdr.) flac. 벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aprokam 50 mg inj. opl. (pdr.) flac.

laboratoires théa - cefuroximnatrium 52 mg - eq. cefuroxim 50 mg - poeder voor oplossing voor injectie - 50 mg - cefuroximnatrium 52 mg - cefuroxime

Levmentin 1 000 mg - 200 mg inj./inf. opl. (pdr.) i.v. flac. 벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

levmentin 1 000 mg - 200 mg inj./inf. opl. (pdr.) i.v. flac.

laboratoires delbert s.a.s. - clavulaanzuur 200 mg; amoxicillinenatrium - eq. amoxicilline 1000 mg - poeder voor oplossing voor injectie/infusie - 1000 mg - 200 mg - clavulaanzuur 200 mg; amoxicillinenatrium - amoxicillin and enzyme inhibitor

Augmentin P 1000 mg - 100 mg inj./inf. opl. (pdr.) i.v. flac. 벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

augmentin p 1000 mg - 100 mg inj./inf. opl. (pdr.) i.v. flac.

glaxosmithkline pharmaceuticals sa-nv - kaliumclavulanaat - eq. clavulaanzuur 100 mg; amoxicillinenatrium - eq. amoxicilline 1000 mg - poeder voor oplossing voor injectie/infusie - 1000 mg - 100 mg - kaliumclavulanaat; amoxicillinenatrium - amoxicillin and enzyme inhibitor

Kefzol 1 g inj. opl. (pdr.) i.v./i.m. flac. 벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kefzol 1 g inj. opl. (pdr.) i.v./i.m. flac.

eurocept international b.v. - cefazolinenatrium - eq. cefazoline 1 g - poeder voor oplossing voor injectie - 1 g - cefazolinenatrium - cefazolin

Kefzol 1 g + Lidocaine inj. opl. (pdr. + oplosm.) i.m. amp. + flac. 벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kefzol 1 g + lidocaine inj. opl. (pdr. + oplosm.) i.m. amp. + flac.

eurocept international b.v. - cefazolinenatrium - eq. cefazoline 1 g - poeder en oplosmiddel voor oplossing voor injectie - cefazolinenatrium - cefazolin; n01bb52 lidocaine, combinations

Insulin aspart Sanofi 유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - insuline aspart - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Sarclisa 유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastische middelen - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Ayvakyt 유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - gastro-intestinale stromale tumoren - andere antineoplastische middelen, proteïne kinase remmers - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

MenQuadfi 유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

menquadfi

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokken - vaccins - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Supemtek 유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccins - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.